These authors contributed equally to this work.
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B†
Version of Record online: 7 FEB 2013
Copyright © 2013 American Association for the Study of Liver Diseases
Volume 57, Issue 3, pages 953–963, March 2013
How to Cite
Esser-Nobis, K., Romero-Brey, I., Ganten, T. M., Gouttenoire, J., Harak, C., Klein, R., Schemmer, P., Binder, M., Schnitzler, P., Moradpour, D., Bartenschlager, R., Polyak, S. J., Stremmel, W., Penin, F., Eisenbach, C. and Lohmann, V. (2013), Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology, 57: 953–963. doi: 10.1002/hep.26260
Potential conflict of interest: Dr. Eisenbach advises and received grants from Roche. He also received grants from MSD.
- Issue online: 28 FEB 2013
- Version of Record online: 7 FEB 2013
- Accepted manuscript online: 15 JAN 2013 12:00AM EST
- Manuscript Accepted: 9 NOV 2012
- Manuscript Received: 10 JUL 2012
- The Deutsche Forschungsgemeinschaft. Grant Numbers: FOR 1202, TP1 and TP3, LO 1556/1-2
- The Swiss National Science Foundation. Grant Number: 31003A-138484
- The french ANRS
- NIH. Grant Numbers: U19AI066328, R01AT006842, R56AI091840
- 5Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp Clin Transplant 2011; 9: 1–6., , , , , , et al.
- 27Safety and anti-HCV effect of prolonged intravenous silibinin in HCV-genotype 1 subjects in the immediate liver transplant period. J Hepatol 2012 [Epub ahead of print]., , , , , , et al.
- 28Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J Hepatol 2012 [Epub ahead of print]., , , , , , et al.